Skip to Main content Skip to Navigation
Journal articles

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers

Abstract : HER2-low breast cancer (i.e., HER 1+ or 2+, without gene amplification) is an emerging subtype for which very few data are available, especially within the triple-negative breast cancer (TNBC) group. Our aim was to evaluate HER2 expression and its prognostic value in a large retrospective series of patients with non-metastatic TNBC (median age: 57.7 years; range: 28.5–98.6). Among the 296 TNBC samples, 83.8% were HER2 0, 13.5% were HER2 1+, and 2.7% were HER2 2+ (HercepTestTM and 2018 ASCO/CAP guidelines for HER2 scoring). CK5/6 and/or EGFR-expressing androgen receptors and FOXA1-expressing tumors were classified as basal-like (63.8%) and molecular apocrine-like (MA, 40.2%), respectively. Compared with HER2 0 tumors, HER2 1+/2+ tumors exhibited a lower histological grade (1/2) (35.4% vs. 18.2%, p = 0.007) and MA profile (57.5% vs. 36.7%, p = 0.008). Moreover, patients with HER2 1+/2+ tumors were older (p = 0.047). After a median follow-up of 9.7 years, HER2 2+ tumors (compared with HER2 0/1+ tumors) were associated with worse relapse-free survival (RFS) (HR = 3.16, 95% CI [1.27; 7.85], p = 0.034) in a univariate analysis. Overall survival (OS) and RFS were not different in the HER2 0 and 1+/2+ groups. HER2 levels were not significantly associated with OS or RFS in a multivariate analysis.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03687874
Contributor : Caroline Mollevi Connect in order to contact the contributor
Submitted on : Friday, June 3, 2022 - 3:57:54 PM
Last modification on : Friday, August 5, 2022 - 10:56:40 AM
Long-term archiving on: : Sunday, September 4, 2022 - 7:30:28 PM

File

cancers-13-06059.pdf
Publisher files allowed on an open archive

Identifiers

Citation

William Jacot, Aurélie Maran-Gonzalez, Océane Massol, Charlotte Sorbs, Caroline Mollevi, et al.. Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers. Cancers, MDPI, 2021, 13 (23), pp.6059. ⟨10.3390/cancers13236059⟩. ⟨inserm-03687874⟩

Share

Metrics

Record views

11

Files downloads

8